The concentration of MIP-1α in PSP-untreated cells (control) was 66.9 ± 45.97 μg/ml and 7120.4 ± 1315 μg/ml in PSP-treated cells, representing a significant increase of MIP-1α in PSP-treated cells with a mean difference of 7005 ± 983.2 μg/ml (Figure 3(h)). The gene discussed is CCL3; the disease is supranuclear palsy, progressive, 1.